German vaccine manufacturer BioNTech, which rose to global prominence with its Covid-19 vaccine developed alongside Pfizer, ...
BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a ...
The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.
In an effort to reallocate resources to its growing oncology focus in the face of shrinking COVID-19 vaccine sales, German ...
BioNTech SE plans to halt operations at several manufacturing sites, affecting as many as 1,860 jobs, due to dwindling demand ...
5dOpinion
BioNTech: Profit takes precedence over health—and 1,860 employees lose their jobs in Germany
The Mainz-based biopharmaceutical company BioNTech is halting COVID-19 vaccine production in Germany, closing almost all its ...
The company said it would exit operations at some manufacturing plants in Germany and Singapore, and that as many as 1,860 ...
BioNTech SE has completed construction at a German facility for making a key ingredient in its messenger-RNA vaccines, the sort of investment that pharma leaders fear is becoming less attractive in ...
Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and combination strategy highlighted through multiple clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results